According to DelveInsight's analysis, the chronic refractory cough market size is expected to increase due to an increase in disease prevalence, the growth in the market of currently approved products, and the expected launch of emerging therapies such as MK-7264 (gefapixant), ORV-PF-01,...
Chronic Refractory Cough Market Still Unexplored, with Pharma Companies Eyeing First-Mover Advantage in the US | DelveInsight
Seaking AlphaSeeking Alpha / Seaking Alpha 9 hours ago 1 Views
Comments